Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

France’s investment banking market recovered strongly in 2025 but that doesn’t mean domestic banks are happy. The market is ...

New long-term clinical data for Blueprint Medicines' drug Ayvakit (avapritinib) were presented at the ASH congress in Orlando, reinforcing the treatment's pr ...

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical ...

The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at [email ...

MILWAUKEE--(BUSINESS WIRE)--Sep 15, 2025--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi .Click here to learn how to join our investigation and obtain … This ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a ...

Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, ...